Sat, Jul 12, 2014, 4:12 AM EDT - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

J. C. Penney Company, Inc. Message Board

meifud 12770 posts  |  Last Activity: 9 hours ago Member since: Dec 1, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • and rexista showed only moderate abuse resistance when mixed with alcohol

  • have been blocked from posting the link no matter how clever i try to change it to get around the censure, but if you do a search for "Northwest Biotherapeutics Stavros Polyzoidis, * Ashkan Keyoumars" it will come up, both abstract and article

    probably getting a lot of attention in the academic community but not in the investment community

  • Reply to

    Unblinded results

    by anotherday1225 Jul 10, 2014 4:58 PM

    agree with last statement, but they did NOT cherry pick when they released info (positive and negative) on ALL 19 that had received 3 injections...

    "Among the 19 patients who have received at least half of the 6 treatments, 11 patients have already shown some preliminary positive responses to the treatments, including the following:

    8 of the 11 patients have shown signs of tumor necrosis (cell death) and immune cell infiltration, as well as stabilized disease that has stopped progressing, following the injections of DCVax-Direct.
    For all of these 8 patients, biopsies indicated substantial to extensive tumor necrosis, as well as substantial accumulations of immune cells infiltrating into and around the patients' tumors, following the DCVax-Direct injections.
    For 6 of these 8 patients, imaging scans also indicated either tumor shrinkage or no disease progression following the DCVax-Direct injections.
    For the other 2 of these 8 patients, imaging scans seemed to indicate some enlargement of their tumors. However, the needle biopsies revealed that the tumor was filled with necrosis (dead tumor cells) and infiltrating immune cells, as noted above. In addition, these patients have reported significant improvement in their physical condition and clinical symptoms.
    The other 3 of the 11 patients have shown stabilized disease, with no growth in their advanced and aggressive tumors following the DCVax-Direct injections, but have not yet shown definitive necrosis or infiltration of immune cells into their tumors.

    Among the remaining 8 of the 19 patients who have received at least half of the 6 injections in the trial:

    1 of these 8 patients requires more data before a preliminary assessment can be made;
    7 of these patients have shown progression of their disease."

  • Reply to

    Unblinded results

    by anotherday1225 Jul 10, 2014 4:58 PM

    zing, they provided info on ALL of the 19 who had received 3 injections...

    "Among the 19 patients who have received at least half of the 6 treatments, 11 patients have already shown some preliminary positive responses to the treatments, including the following:

    8 of the 11 patients have shown signs of tumor necrosis (cell death) and immune cell infiltration, as well as stabilized disease that has stopped progressing, following the injections of DCVax-Direct.
    For all of these 8 patients, biopsies indicated substantial to extensive tumor necrosis, as well as substantial accumulations of immune cells infiltrating into and around the patients' tumors, following the DCVax-Direct injections.
    For 6 of these 8 patients, imaging scans also indicated either tumor shrinkage or no disease progression following the DCVax-Direct injections.
    For the other 2 of these 8 patients, imaging scans seemed to indicate some enlargement of their tumors. However, the needle biopsies revealed that the tumor was filled with necrosis (dead tumor cells) and infiltrating immune cells, as noted above. In addition, these patients have reported significant improvement in their physical condition and clinical symptoms.
    The other 3 of the 11 patients have shown stabilized disease, with no growth in their advanced and aggressive tumors following the DCVax-Direct injections, but have not yet shown definitive necrosis or infiltration of immune cells into their tumors.

    Among the remaining 8 of the 19 patients who have received at least half of the 6 injections in the trial:

    1 of these 8 patients requires more data before a preliminary assessment can be made;
    7 of these patients have shown progression of their disease."

  • you really got a lot to learn, kiddo
    it is you and YOUR motives that have folks here wondering

    you admit nobody knows what is going on behind the scenes and then you proceed to create scenarios more creative than anything since the defense at the OJ trial

    your non-stop baseless cheerleading does nothing but exhaust people reading this board, and your projections for the generics have been WAY off and distracting

    the abuse resistant line will take care of itself one way or the other in due time, so stop trying to dominate this board with nonsense that really just speak to your need for action even as you profess to being a long term investor

    suspect you have a gambling problem

  • you completely miss the point
    there is a whole lot of space between buying the company and doing nothing
    and NOTHING is happening in that space, understand?
    forget about someone buying the whole company -- they aren't even buying the stock!

    geez, it's like talking to a democrat...

  • the activist posters on this board should try disseminating this positive information on facebook, twitter, and the news media instead of attacking MD Anderson

  • "at this level" was referring to the stage in the process of getting approval, not the price of the stock
    institutions of SOME size (tiny, small, big, magnificent) would be happy to buy a penny stock, a two bit stock ($.25), or any priced stock once a company has evidence that their intellectual property has value
    elite's intellectual property is certainly intriguing to you and i, but institutions have yet to buy into our optimism -- in fact, they didn't even agree it was worth 7-8 cents when we were buying
    so, while it may feel nice to daydream about 5, 15, or why not 50 dollars a share, keep in mind that whatever institutions are out there that are interested in these upstart micro pharmas -- they are almost unanimous in not believing the two-bead will work

  • so why aren't institutions buying the stock
    why would they be passing up a 40-banger if they did not still see high hurdles to come

  • cannot believe that people do not understand what has been revealed

    ipci's generic druglettes are NOT going to sell like cheerleaders here kept saying

    the only hope is rexista but it is years away and many millions of dollars out of their reach

    by the time it happens, if ever, there will be other, better, abuse resistant products available

  • meifud meifud Jul 10, 2014 9:56 AM Flag

    why was this never given a press release or mentioned in a SEC filing

  • meifud meifud Jul 10, 2014 9:52 AM Flag

    great, but we don't know if they ever even enrolled anyone -- or if the deadline can or needs to be extended
    so, why is this even on the board

    without any introduction or statement of any kind by the poster, this is being presented as a new announcement and, frankly, some people are going to think it is a setback because they were thinking the trials had been ongoing in UK, not just starting

  • "Presently in the U.K. the product may be offered to a limited quota of patients on a compassionate basis outside the trial. Though this is distinct from a formal approval, it does signify the potential that DCVax®-L technology carries and its favorable safety profile. Very recently DCVax®-L received a similar approval from the PEI in Germany. Moreover the German reimbursement authority (Institut Für Das Entgeltsystem Im Krankenhaus, or InEK) has rulled that DCVax®-L for gliomas is eligible for reimbursement from the Sickness Funds (health insurers) of the German healthcare system. Furthermore both in the U.S.A. and in Europe DCVax®-L has been granted orphan drug status for GBM and other gliomas. As a result DCVax®-L will have market exclusivity for 7 years in the U.S.A. and 10 years in Europe."

  • meifud meifud Jul 10, 2014 9:38 AM Flag

    breath of fresh air, please

  • meifud meifud Jul 9, 2014 11:21 PM Flag

    seems you are just trying to make this look like something new
    makes no sense to post an announcement from a year and a half ago
    why not go back a couple more years and find some more 'news'
    if your point is to remind us that enrollment is supposed to finish this month, why don't you say that

  • it's just that a whole lot more people finally woke up
    but it's the same company, the same one that so many pompom pumpers here had been touting

  • meifud meifud Jul 9, 2014 10:32 PM Flag

    and already you sold out
    ward's not going to like that
    might be hard on the beaver tonight

  • Reply to

    Day after day...Gregory / Meifud SAME shorts BS...

    by check__6 Jun 24, 2014 8:42 AM
    meifud meifud Jul 9, 2014 8:49 PM Flag

    more like everybody BUT you is selling

    if you had paid more attention to the company instead of wasting energy attacking posters on this board you would have seen this coming

    now you are among the crowd claiming you were duped
    well, it seems those of us who were open-minded and not lashing out at others were not duped

    so, next time, listen to what other posters are saying and read, read, read the SEC filings

  • meifud meifud Jul 9, 2014 8:37 PM Flag

    did ms.cleaver stop to apologize to you for all the insults and ridicule, or did she just pack up her beaver and leave

  • meifud meifud Jul 9, 2014 8:27 PM Flag

    whew, you shouldn't be allowed to invest without adult supervision

    but thanks to folks like you who are dumb enough to think a downgrade makes a stock go up that a lot of others were able to sell today for more than the stock otherwise would have been

    keep holding tight because there are more folks who will want to thank you when they sell tomorrow

JCP
8.75+0.01(+0.11%)Jul 11 4:01 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.